These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 6976793)

  • 61. [Alpha interferon treatment of chronic myeloproliferative disease associated thrombocytosis].
    Remes K; Pelliniemi TT
    Duodecim; 1993; 109(11):983-9. PubMed ID: 8062671
    [No Abstract]   [Full Text] [Related]  

  • 62. Fertility, pregnancy and the management of myeloproliferative disorders.
    Griesshammer M; Bergmann L; Pearson T
    Baillieres Clin Haematol; 1998 Dec; 11(4):859-74. PubMed ID: 10640221
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis.
    Wang JC; Chen C; Novetsky AD; Lichter SM; Ahmed F; Friedberg NM
    Am J Med; 1998 May; 104(5):451-5. PubMed ID: 9626028
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
    Shaikh MS; Shaikh MU; Adil SN; Khurshid M; Ahmed ZA
    J Ayub Med Coll Abbottabad; 2016; 28(2):293-297. PubMed ID: 28718562
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
    Berild D; Hasselbalch H; Knudsen JB
    Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk of leukemic transformation in PV and ET patients.
    Chomienne C; Rain JD; Brière J;
    Pathol Biol (Paris); 2004 Jun; 52(5):289-93. PubMed ID: 15217716
    [TBL] [Abstract][Full Text] [Related]  

  • 67. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.
    Yataganas X; Meletis J; Plata E; Viniou N; Deligiannis F; Tsekoura C; Voscaridou E; Boussiotis V; Rombos J; Vayopoulos G
    Eur J Cancer; 1991; 27 Suppl 4():S69-71. PubMed ID: 1799484
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
    Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B
    J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
    Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
    Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
    Todisco G; Manshouri T; Verstovsek S; Masarova L; Pierce SA; Keating MJ; Estrov Z
    Leuk Lymphoma; 2016 May; 57(5):1054-9. PubMed ID: 26402369
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Polycythaemia vera and myelofibrosis.
    Ikkala E; Rapola J; Kotilainen M
    Scand J Haematol; 1967 Dec; 4(6):453-64. PubMed ID: 6082224
    [No Abstract]   [Full Text] [Related]  

  • 74. [Status and perspectives on chronic myeloproliferative neoplasm treatment].
    Ocias LF; Holmström MO; Riley CH; Andersen CL; Rønnov-Jessen D; Starklint J; Frederiksen M; Steffensen MS; Bjerrum OW; Farmer S; Mourits-Andersen T; Hasselbalch HC; Larsen TS
    Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967090
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myeloproliferative syndromes and the associated risk of coronary artery disease.
    Ganti AK; Potti A; Koka VK; Pervez H; Mehdi SA
    Thromb Res; 2003 May; 110(2-3):83-6. PubMed ID: 12893021
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Medical Grand Rounds--chronic granulocytic leukemia with thrombocytosis; the hypercoagulability states.
    Kossmann CE; Hubbard WS; Chesney CM
    J Tenn Med Assoc; 1981 Oct; 74(10):742-3, 745. PubMed ID: 6947124
    [No Abstract]   [Full Text] [Related]  

  • 78. Myeloproliferative disorders.
    Schwartz SI
    Ann Surg; 1975 Oct; 182(4):464-71. PubMed ID: 1058648
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.
    Cashell AW; Buss DH
    Ann Hematol; 1992 Jun; 64(6):273-6. PubMed ID: 1637881
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels.
    Español I; Hernández A; Cortés M; Mateo J; Pujol-Moix N
    Haematologica; 1999 Apr; 84(4):312-6. PubMed ID: 10190944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.